Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Recruiting 4Active not recruiting 2

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Burkitt Lymphoma 19Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Leukemia 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Blast Crisis 2Recurrence 1Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Hematologic Neoplasms 1Down Syndrome 1

Interventions

Cytarabine 7Cyclophosphamide 7Dexamethasone 6venetoclax 4blinatumomab 4Methotrexate 4Inotuzumab Ozogamicin 4pegaspargase 3merphos 3Vincristine 3Specimen Handling 3prednylidene 2dexamethasone acetate 2dexamethasone 21-phosphate 2deltacortene 2calaspargase pegol 2azathiopurine 2auricularum 2Prednisone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Calcium Dobesilate 2Biopsy 2Asparaginase 2trametinib 1ruxolitinib 1olverembatinib 1ofatumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × blinatumomab × Clear all
NCT02877303 2026-05-20

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03959085 2026-05-05

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Children's Oncology Group

Phase 3 Recruiting
5,951 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Biphenotypic, Acute

NCT06742515 2024-12-19

Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06554626 2024-08-15

Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡